Review of variation between clinical and pathological TNM staging in real-life cases of non-small cell lung cancer

Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. S10
Author(s):  
D. Reed ◽  
E. Shaw ◽  
S. Savory ◽  
R. Panchal ◽  
S. Agrawal ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real Life ◽  
Tnm Staging ◽  
Small Cell ◽  
Small Cell Lung

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

Lung Cancer ◽  
2019 ◽  
Vol 127 ◽  
pp. 96-102 ◽  
Author(s):  
Jean Bernard Auliac ◽  
Maurice Pérol ◽  
David Planchard ◽  
Isabelle Monnet ◽  
Marie Wislez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real Life ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Pretreated Patients ◽  
Egfr T790m

Prognostic Value of TNM Staging in Small Cell Lung Cancer

1998 ◽  
Vol 45 (2) ◽  
pp. 322
Author(s):  
Jae Yong Park ◽  
Kwan Young Kim ◽  
Sang Cheol Chae ◽  
Jeong Seok Kim ◽  
Kwon Yeop Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Tnm Staging ◽  
Small Cell ◽  
Small Cell Lung

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Lung Cancer ◽  
2018 ◽  
Vol 126 ◽  
pp. 217-223 ◽  
Author(s):  
Elizabeth Dudnik ◽  
Mor Moskovitz ◽  
Sameh Daher ◽  
Sivan Shamai ◽  
Ekaterina Hanovich ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real Life ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Real ◽  
Life Data ◽  
Real Life Data

Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection

2018 ◽  
Vol 34 (9) ◽  
pp. 1687-1694 ◽  
Author(s):  
Vítězslav Kolek ◽  
Stanislav Losse ◽  
Juraj Kultan ◽  
Petr Jakubec ◽  
Zatloukal Jaromir ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real Life ◽  
Complete Resection ◽  
Small Cell ◽  
Small Cell Lung

Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer

Immunotherapy ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 235-243 ◽  
Author(s):  
Daniel Reinhorn ◽  
Oded Jacobi ◽  
Oded Icht ◽  
Elizabeth Dudnik ◽  
Ofer Rotem ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Real Life ◽  
Small Cell ◽  
Small Cell Lung ◽  
Treatment Beyond Progression

Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP) in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. Materials & methods: We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. Results: Of 207 patients included in this analysis, 22% patients received TBP. A total of 36% achieved a clinical benefit. A total of 27% patients had a progression-free interval over 6 months after receiving TBP. Conclusion: A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.

Sign in / Sign up

Export Citation Format

Share Document